Liraglutide, a GLP-1 analog with 97% amino acid homology to endogenous substances (Knudsen and Lau, 2019), has been used as a GLP-1 receptor agonist for the treatment of type 2 diabetes (T2D) for more than 10 years (Knudsen and Lau, 2019; Nauck et al., 2021a), and its safety, tolerability, and pharmacodynamics have been effectively demonstrated clinically. This evidence concerns the gene GCG and type 2 diabetes mellitus.